Noxxon Pharma N.V. announced an agreement with Aptarion biotech AG to license enabling technology, assign certain preclinical and technology spiegelmer research programs and transfer lab assets in exchange for cash, royalties and an equity stake in Aptarion. NOXXON and Aptarion are based in Germany. Aptarion is engaged in the research and development of biostable L-aptamers.